Nanshan School, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
J Dig Dis. 2021 Feb;22(2):62-71. doi: 10.1111/1751-2980.12966.
Gallbladder cancer (GBC) is the most common form of biliary tract malignancy with a dismal prognosis. A poor outcome in patients with GBC is related to the aggressive nature of the tumor, delayed diagnosis, and a lack of reliable biomarkers and effective treatment. Therefore, early diagnosis and accurate disease assessment are crucial to prolonging the patient survival. Identification of novel prognostic and diagnostic biomarkers may help improve the early diagnostic rate and develop specific targeted treatments for patients with GBC. We herein review the novel biomarkers that may be associated with the diagnosis and prognosis in GBC and their potential clinical significance in the management of GBC.
胆囊癌（GBC）是最常见的胆道恶性肿瘤，预后较差。GBC 患者的不良预后与肿瘤的侵袭性、诊断延迟以及缺乏可靠的生物标志物和有效的治疗方法有关。因此，早期诊断和准确的疾病评估对于延长患者生存至关重要。鉴定新的预后和诊断生物标志物可能有助于提高 GBC 的早期诊断率，并为 GBC 患者开发特异性靶向治疗。本文综述了可能与 GBC 诊断和预后相关的新型生物标志物及其在 GBC 管理中的潜在临床意义。
